Compare Bristol-Myers Squibb Co (BMY) vs Exxon Mobil Corporation (XOM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Exxon Mobil Corporation — how do they compare? Bristol-Myers Squibb Co trades at $56.99 (market cap $116.30B), while Exxon Mobil Corporation trades at $145 (market cap $601.39B). The key difference: Exxon Mobil Corporation is far larger — about 5.2× Bristol-Myers Squibb Co's market cap, and Bristol-Myers Squibb Co pays the higher dividend (4.42%). Which is the better fit depends on your goals.
| BMY | XOM | |
|---|---|---|
Market Cap | $116.30B | $601.39B |
Sector | Health | Energy |
52-Week High | $62.37 | $171.52 |
52-Week Low | $42.60 | $105.83 |
Enterprise Value | $152.24B | $640.62B |
Dividend Yield | 4.42% | 2.84% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
ExxonMobil (XOM) trades at $144.51, up 4.1% today, with a bullish technical outlook and strong earnings beats in recent quarters. The stock shows robust profitability with a net income margin of 7.76% and a solid balance sheet, though revenue and net income have declined from 2022 peaks. Recent news highlights Exxon's Permian Basin advantages and potential oil price spikes, supporting positive sentiment.
XOM offers value with a consensus price target of $169.30, implying 17% upside, but faces risks from volatile oil prices and declining profit margins. Institutional buy ratings at 40.74% reflect cautious optimism, while technical indicators suggest near-term resistance at $146. Investors should weigh the strong cash flow and dividend against energy market uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Exxon Mobil Corporation
Exxon Mobil Corporation operates petroleum and petro chemicals businesses. The Company provides operations include exploration and production of oil and gas, electric power generation, and coal and minerals operations. Exxon Mobil also manufactures and markets fuels, lubricants, and chemicals. Exxon Mobil serves customers worldwide.
Read more on XOM →
